ISTO Technologies Announces Participation in Canaccord Genuity Musculoskeletal Conference

ST. LOUIS, March 13, 2013 (GLOBE NEWSWIRE) -- ISTO Technologies, Inc., a privately-held orthobiologics company, announced today that it is participating in the 8th Annual Canaccord Genuity to be held on Tuesday, March 19, 2013 at The Westin Michigan Avenue in Chicago, IL. Mitchell Seyedin, Ph.D., President and Chief Executive Officer, will be presenting at 3:20 PM (CDT) in the Huron A Room. The conference, directly preceding the American Academy of Orthopaedic Surgeons Annual Meeting, will feature presentations from over 60 public and private companies and explore the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.

ISTO's proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. The company believes that the two clinical-stage products currently comprising ISTO's cell-based program, DeNovo® ET and NuQu®, potentially represent breakthrough technologies addressing two significant unmet medical needs: damaged knee cartilage and discogenic back pain. These products utilize juvenile chondrocytes that have a proven superior capacity for cartilage regeneration compared to adult cells.

In addition to ISTO's cell-based cartilage programs, the company is currently manufacturing and marketing InQu®, a bone graft extender and substitute. InQu combines integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications. InQu has been used in over 20,000 surgeries at U.S. hospitals to date.

About ISTO

ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at

CONTACT: ISTO Technologies, Inc. Scott Gill Chief Financial Officer (314) 995-6049 The Ruth Group Nick Laudico (investors) (646) 536-7030 Lisa Cook (media) (646) 536-7012 lcook@theruthgroup.comSource: ISTO